Assertio Holdings, Inc. Q4 FY2025 earnings call

First, Mark Eisenhower mentioned that since acquiring Rolvidon in 2023, the team has integrated the organization, completed the integration in the fourth quarter of 2025, positioning the product for commercial success, with Rolvidon expected to start regular sales in the second quarter of 2026. Second, the company has a commercial platform centered on the community oncology channel, including a field organization, national accounts team, etc., with scalable infrastructure. Third, Paul stated that the integration of Rolvidon from Spectrum to the Assertio platform is complete, and in 2026, it will continue to integrate other products, and the organization has made personnel and process enhancements.

Fourth quarter total product sales were $12.8 million, compared to $29.6 million in the prior year, mainly driven by the timing of channel inventory related to Rolvidon sell-in. Rolvidon net sales products were $0.4 million in the fourth quarter, down from $15.4 million in the prior year quarter. Simpizen sales were $3.1 million in the fourth quarter, up from $2.5 million in the prior year. Indusyn sales in the fourth quarter were flat year over year at $5.5 million. Full year total product sales were $117.1 million. Rolvidon sales were $68.2 million, up from $60.1 million in the prior year. Indusyn net product sales were $18.9 million for 2025. For fiscal 2026, revenue guidance is in the range of $110 million to $125 million and adjusted EBITDA guidance between $28 million and $40 million.

For fiscal 2026, revenue is guided in the range of $110 million to $125 million, and adjusted EBITDA is guided between $28 million and $40 million. The growth in 2026 is expected to be driven by Rolvidon's demand growth offsetting the decline of legacy assets, and achieved through high-margin revenue growth and structural cost savings.

Forward-looking statements involve risks and uncertainties, including those noted in SEC filings, and actual results may differ materially from forward-looking statements. Specific risks are more fully described in the company's annual report on Form 10-K and Form 10-Q filings.

Q: Regarding the types of assets to be sought in the oncology field, A: On market, late-stage development, therapeutic products, preferably past proof of concept.

Q: Is incremental investment required to introduce products with the existing commercial infrastructure, A: Likely a small increment.

Q: Confidence in Rolvidon's growth in 2026 and plans for expansion outside the community, A: There was 32% year-over-year demand growth in 2025 full year, expected to continue adding new accounts in 2026, plan to continue focusing on the community Medicare Part B field and evaluate other fields.

Q: Rolvidon label change in 2026 and Indosyn product situation, A: The transition of Rolvidon label is smooth, quarterly demand in 2026 is generally in line with shipments, Indosyn faces generic competition and is expected to have at least one new generic in 2026.

Q: Sustainability of SG&A in the fourth quarter of 2025, A: SG&A in 2026 is expected to decline due to factors like reduced litigation expenses.

Q: Detailed expectations of Rolvidon's net sales in 2026 and long-term potential, A: Guidance doesn't provide product-level details, but Rolvidon's growth is expected to offset the decline of tail assets, and long-term potential is expected to exceed $100 million.